A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00257608
Recruitment Status : Completed
First Posted : November 23, 2005
Results First Posted : March 15, 2016
Last Update Posted : April 18, 2016
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: bevacizumab Drug: placebo Drug: erlotinib HCl Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1145 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer
Study Start Date : January 2006
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: bevacizumab
Intravenous repeating dose
Drug: erlotinib HCl
Oral repeating dose
Placebo Comparator: 2 Drug: bevacizumab
Intravenous repeating dose
Drug: placebo
Oral repeating dose

Primary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Approximately 3 years ]
    PFS was defined as the length of time from randomization until documented disease progression or death from any cause, whichever occurred earlier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Data presented until cut-off date 18 July 2008.

Secondary Outcome Measures :
  1. Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Chemotherapy Phase [ Time Frame: Approximately 3 years ]
    Treatment-emergent adverse events were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.. Number of participants who had Grade >=3TEAEs of pulmonary hemorrhage, gastrointestinal (GI) perforation, arterial thromboembolic (ATE) events, proteinuria, congestive heart failure (CHF), and hypertension were presented. Data presented up to data cutoff 18 July 2008.

  2. Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Post-Chemotherapy Phase [ Time Frame: Approximately 3 years ]
    Treatment-related adverse events are defined as new events that occur following subject entry into the study or events that worsen following study entry state and are judged by the investigator to be possibly, probably or definitely related to study medication. Pulmonary hemorrhage, GI perforation, ATE events, proteinuria, CHF, and hypertension were prospectively identified TEAEs of grade >=3. Data presented until cut-off date 28 January 2009.

  3. Number of Participants With Any Adverse Events During Post-Chemotherapy Phase [ Time Frame: Approximately 3.5 years ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event. Data presented up to data cutoff 19 June 2009.

  4. Incidence of Study Treatment Discontinuation for Reasons Other Than Disease Progression in Chemotherapy Phase [ Time Frame: Approximately 3 years ]
    Participants who experienced disease progression were discontinued from the study. Data presented up to data cutoff (18 July 2008).

  5. Incidence of Study Treatment Discontinuation [ Time Frame: Approximately 3 years ]
    Participants in post-chemotherapy phase were discontinued from the study for the reasons other than disease progression. Data presented Up to data cutoff 18 July 2008.

  6. Overall Survival [ Time Frame: Approximately 3.5 years ]
    Overall survival was defined as the length of time from randomization to death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed Informed Consent Form
  • Histologically or cytologically confirmed NSCLC
  • Advanced NSCLC or recurrent disease
  • INR no greater than 1.3 and aPTT no greater than upper limits of normal (ULN) within 28 days prior to enrollment for subjects not on low molecular weight heparin or fondaparinux. Subjects on low molecular weight heparin or fondaparinux are not required to meet INR or aPTT limits. Chronic full-dose anticoagulation with warfarin is not permitted.
  • 18 years of age or older
  • For women of childbearing potential and sexually active men, use of an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to enrollment and for the duration of the study

Exclusion Criteria:

  • Prior systemic chemotherapy in the metastatic setting
  • Treatment with an investigational or marketed agent that acts by either EGFR inhibition or anti-angiogenesis mechanisms
  • Pregnancy or lactation
  • Any other medical condition, including mental illness or substance abuse, deemed by the clinician to be likely to interfere with a subject's ability to provide informed consent, cooperate, and participate in the study, or to interfere with the interpretation of the results
  • Active infection or a fever within 3 days of enrollment
  • Active malignancy other than lung cancer
  • Radiation therapy to sites other than whole brain within 14 days prior to enrollment
  • History of gross hemoptysis within 3 months prior to enrollment
  • Known hypersensitivity to any of the components of cytotoxic chemotherapy combinations, bevacizumab, or tyrosine kinase inhibitors
  • Inadequately controlled hypertension
  • Unstable angina or New York Heart Association Grade II or greater CHF
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment
  • History of myocardial infarction within 6 months prior to enrollment
  • History of stroke within 6 months prior to enrollment
  • Symptomatic peripheral vascular disease within 6 months prior to enrollment
  • Evidence of bleeding diathesis or coagulopathy
  • Serious, non-healing wound, ulcer, or bone fracture
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment; anticipation of need for major surgical procedure during the course of the study
  • Current, recent, or planned participation in an experimental drug study other than this Genentech-sponsored bevacizumab/erlotinib study
  • Progressive neurologic symptoms in subjects with a history of brain metastases
  • History of significant vascular disease (e.g., aortic aneurysm)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00257608

  Hide Study Locations
United States, Alabama
Sacred Heart Medical Onc Group
Mobile, Alabama, United States, 36608
United States, Arizona
St. Edward Mercy Medical Ctr
Ft Smith, Arizona, United States, 72917
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
Central Hem/Onc Medical Group
Alhambra, California, United States, 91801
Comp Blood & Cancer Center
Bakersfield, California, United States, 93309
South Bay Oncology
Campbell, California, United States, 95008
Bay Area Cancer Research Grp
Concord, California, United States, 94598
Pacific Onc & Hem Assoc
Encinitas, California, United States, 92024
Pacific Coast Hem/Onc
Fountain Valley, California, United States, 92708
Cancer Care Associates
Fresno, California, United States, 93720
St. Jude Heritage Med Group
Fullerton, California, United States, 92835
Ronald H. Yanagihara
Gilroy, California, United States, 95020
Glendale Adventist Medical Ctr
Glendale, California, United States, 91206
Scipps Clinic
La Jolla, California, United States, 92037-1027
Loma Linda Univ Medical Center
Loma Linda, California, United States, 92354
Pacific Shores Medical Group
Long Beach, California, United States, 90813
Kenmar Research Institute LLC
Los Angeles, California, United States, 90057
UCLA Medical Ctr
Los Angeles, California, United States, 90095
Sutter Gould Med Foundation
Modesto, California, United States, 95355
North Valley Hem Onc Med Grp
Northridge, California, United States, 91325
Hem Onc Med Grp Orange Cty
Orange, California, United States, 92868
Medical Oncology Care Assoc
Orange, California, United States, 92868
Ventura Co Hem-Onc Specialists
Oxnard, California, United States, 93030
Wilshire Oncology Medical Grp
Pomona, California, United States, 91767
Sutter Cancer Center
Sacramento, California, United States, 95816
Mercy General Hospital
Sacramento, California, United States, 95819
Los Palos Oncology & Hem
Salinas, California, United States, 93901
Kaiser Permanente
San Diego, California, United States, 92120
Naval Medical Center
San Diego, California, United States, 92134
Pacific Hematology Oncology
San Francisco, California, United States, 94115
Kaiser Permanente Santa Teresa
San Jose, California, United States, 95119
Sansum Medical Clinic, Inc.
Santa Barbara, California, United States, 93105
Santa Barbara Hem Onc Med Grp
Santa Barbara, California, United States, 93105
Central Coast Medical Oncology
Santa Maria, California, United States, 93454
The Angeles Clinic
Santa Monica, California, United States, 90404
Redwood Regional Med Grp
Santa Rosa, California, United States, 95403
Cancer Care Associates
Torrance, California, United States, 90505
United States, Colorado
Mile High Oncology
Denver, Colorado, United States, 80210
Front Range Cancer Specialists
Fort Collins, Colorado, United States, 80524
United States, District of Columbia
Washington Onc Hem Center PC
Washington, District of Columbia, United States, 20037
United States, Florida
Center for Hematology-Oncology
Boca Raton, Florida, United States, 33486
Halifax Medical Center
Daytona Beach, Florida, United States, 32115
Florida Wellcare Alliance
Inverness, Florida, United States, 34452
Baptist Cancer Institute
Jacksonville, Florida, United States, 32207
Jackson Memorial Hospital
Miami, Florida, United States, 33136
Mid-Florida Hem Oncology Ctr
Orange City, Florida, United States, 32763
Integrated Comm Onc Network
Orange Park, Florida, United States, 32073
Hematology Onc Treasure Coast
Port Saint Lucie, Florida, United States, 34952
United States, Georgia
Phoebe Putney Cancer Center
Albany, Georgia, United States, 31701
Northeast Georgia Cancer Care
Athens, Georgia, United States, 30607
Suburban Hem-Onc Associates
Lawrenceville, Georgia, United States, 30045
Northwest Georgia Onc Centers
Marietta, Georgia, United States, 30060
United States, Illinois
Chicagoland Hematology Onc
Arlington Heights, Illinois, United States, 60005
Weiss-Strauss Oncology Center
Chicago, Illinois, United States, 60640
LaGrange Oncology Associates
Geneva, Illinois, United States, 54301
La Grange Oncology Associates
Lagrange, Illinois, United States, 60525
Associates in Medical Oncology
Oak Lawn, Illinois, United States, 60453
Onc Hem Assoc of Central IL
Peoria, Illinois, United States, 61615
West Suburban Cancer Center
River Forest, Illinois, United States, 60305
OSF St. Anthony Med Ctr
Rockford, Illinois, United States, 61108
United States, Indiana
Community Hospital
Munster, Indiana, United States, 46321
Providence Medical Group
Terre Haute, Indiana, United States, 47802
United States, Iowa
Hematology Oncology Associates
Bettendorf, Iowa, United States, 52722
Siouxland Hem-Onc Assoc LLP
Sioux City, Iowa, United States, 51101
Covenant Clinic
Waterloo, Iowa, United States, 50702
United States, Kentucky
Gajera & Patel, PLLC
Hopkinsville, Kentucky, United States, 42240
Kentuckiana Cancer Center
Louisville, Kentucky, United States, 40202
University of Louisville
Louisville, Kentucky, United States, 40202
Consultants in Blood Disorders
Louisville, Kentucky, United States, 40207
Owensboro Medical Health Sys
Owensboro, Kentucky, United States, 42303
United States, Louisiana
Willis-Knighton Cancer Center
Shreveport, Louisiana, United States, 71103
United States, Maryland
H&J Weinberg Cancer Institute
Baltimore, Maryland, United States, 21237
Oncology Hematology Associates
Clinton, Maryland, United States, 20735
Maryland Oncology/Hema PA
Columbia, Maryland, United States, 21044
Frederick Memorial Hospital
Frederick, Maryland, United States, 21701
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Caritas St. Elizabeth Med Ctr
Boston, Massachusetts, United States, 02135
Lahey Clinic Med Ctr
Burlington, Massachusetts, United States, 01805
Metrowest Cancer Center
Framingham, Massachusetts, United States, 01702
Baystate Medical Center
Springfield, Massachusetts, United States, 01107
United States, Michigan
Spectrum Health
Grand Rapids, Michigan, United States, 49503
Kalamazoo Hem & Onc
Kalamazoo, Michigan, United States, 49048
Marquette General Health Sys
Marquette, Michigan, United States, 49855
St. Joseph Mercy Oakland
Pontiac, Michigan, United States, 48341
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, Minnesota
Virginia Piper Cancer Inst
Minneapolis, Minnesota, United States, 55407
United States, Missouri
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65203
Freeman Cancer Institute
Joplin, Missouri, United States, 64804
St. Louis Univ Care Center
Saint Louis, Missouri, United States, 63117
Missouri Cancer Center, PC
St Charles, Missouri, United States, 63301
Arch Medical Services
Washington, Missouri, United States, 63090
United States, Montana
Billings Clinic
Billings, Montana, United States, 59101
Big Sky Oncology
Great Falls, Montana, United States, 59405
Montana Cancer Specialists
Missoula, Montana, United States, 59802
United States, Nebraska
NE Hematology Oncology, PC
Lincoln, Nebraska, United States, 68506
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, Nevada
Comp Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89109
United States, New Jersey
Ctr for Cancer & Hem Disease
Cherry Hill, New Jersey, United States, 08003
Forte, Attas & Schleider
Englewood, New Jersey, United States, 07631
Hunterdon Medical Center
Flemington, New Jersey, United States, 08822
Central State Medical Center
Freehold, New Jersey, United States, 07728
St. Barnabas Health Care Sys
Livingston, New Jersey, United States, 07039
Mountainside Hospital
Montclair, New Jersey, United States, 07042
Morristown Memorial Hospital
Morristown, New Jersey, United States, 07962
Hematology Oncology Assoc SJ
Mount Holly, New Jersey, United States, 08060
Jersey Shore Medical Center
Neptune, New Jersey, United States, 07754
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
The Valley Hospital
Paramus, New Jersey, United States, 07652
Overlook Hospital
Summit, New Jersey, United States, 07902
Holy Name Hospital
Teaneck, New Jersey, United States, 07666
United States, New Mexico
San Juan Onco Assoc
Farmington, New Mexico, United States, 87401
United States, New York
Zale P Bernstein MD - PP
Buffalo, New York, United States, 14215
Bassett Cancer Center
Cooperstown, New York, United States, 13326
Adriondack Cancer Care
Glen Falls, New York, United States, 12801
Great Neck, New York, United States, 11021
Queens Cancer Center
Jamaica, New York, United States, 11432
Crystal Run Health Care
Middletown, New York, United States, 10941
NYU Medical Center
New York, New York, United States, 10016
Mem Sloan Kettering Cancer Ctr
New York, New York, United States, 10021
SUNY Upstate
Syracuse, New York, United States, 13210
United States, North Carolina
Presbyterian Hospital
Charlotte, North Carolina, United States, 28204
NorthEast Medical Center
Concord, North Carolina, United States, 28025
Moses Cone Reg Cncr Ctr
Greensboro, North Carolina, United States, 27403
Emerywood Hematology Oncology
High Point, North Carolina, United States, 27262
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Kinston Medical Specialists
Kinston, North Carolina, United States, 28501
Beaufort County Hospital
Washington, North Carolina, United States, 27889
United States, Ohio
Summa Health System
Akron, Ohio, United States, 44304
Akron General Medical Center
Akron, Ohio, United States, 44307
Aultman Hospital
Canton, Ohio, United States, 44710
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Onc/Hem Care Clin Trials LLC
Cincinnati, Ohio, United States, 45242
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
Mid Ohio Onc Hematology Inc
Columbus, Ohio, United States, 43213
Riverside Methodist Hospital
Columbus, Ohio, United States, 43214
Dayton Clinical Oncology Prog
Dayton, Ohio, United States, 45429
Ohio Cancer Specialists
Mansfield, Ohio, United States, 44907
Signal Point Hem/Oncology Inc
Middletown, Ohio, United States, 45042
Toledo Community Hospital
Toledo, Ohio, United States, 43623
Forum Health Cancer Care Ctr
Youngstown, Ohio, United States, 44501
United States, Oregon
Providence Portland Med Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
Ephrata Cancer Center
Ephrata, Pennsylvania, United States, 17543
Armstrong County Memorial Hosp
Kittanning, Pennsylvania, United States, 16201
Hem Onc Assoc Phys Lancaster
Lancaster, Pennsylvania, United States, 17604
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Scranton Hematology Oncology
Scranton, Pennsylvania, United States, 18510
Assoc in Hematology Oncology
Upland, Pennsylvania, United States, 19013
Lankenau Medical Office Bldg
Wynnewood, Pennsylvania, United States, 19096
United States, South Carolina
Charleston Cancer Center
Charleston, South Carolina, United States, 29406
Palmetto Hematology Oncology
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Erlanger Health Systems
Chattanooga, Tennessee, United States, 37403
The Jones Clinic
Germantown, Tennessee, United States, 38138
Jackson-Madsion County Hosp
Jackson, Tennessee, United States, 38301
Clopton Clinic
Memphis, Tennessee, United States, 38138
Sarah Cannon Cancer Center
Nashville, Tennessee, United States, 37203-1632
Vanderbilt University Medical
Nashville, Tennessee, United States, 37232
United States, Texas
Lone Star Oncology Consultants
Austin, Texas, United States, 78759
Coastal Bend Cancer Center
Corpus Christi, Texas, United States, 78404
Texas Cancer Associates
Dallas, Texas, United States, 75231
Texas Hematology Oncology
Dallas, Texas, United States, 75234
JPS Center for Cancer Care
Fort Worth, Texas, United States, 76104
Univ of Texas Medical Branch
Galveston, Texas, United States, 77555
Wilford Hall Medical Center
Lackland AFB, Texas, United States, 78236
United States, Vermont
SW Vermont Healthcare Onc Asoc
Bennington, Vermont, United States, 05201
Vermont Ctr Cancer Medicine
Colchester, Vermont, United States, 05446
Community Cancer Center
Rutland, Vermont, United States, 05701
United States, Virginia
Peninsula Cancer Institute
Newport News, Virginia, United States, 23606
SW Virginia Hem Onc
Roanoke, Virginia, United States, 24014
United States, Washington
Cascade Cancer Center
Kirkland, Washington, United States, 98034
Northwest Medical Specialists
Tacoma, Washington, United States, 98405
United States, West Virginia
Univ Physicians Internal Med
Huntington, West Virginia, United States, 25701
West Virginia University
Morgantown, West Virginia, United States, 26506
United States, Wisconsin
Oncology Alliance
Glendale, Wisconsin, United States, 53212
Dean Clinic
Madison, Wisconsin, United States, 53715
Medical Consultants LTD
Milwaukee, Wisconsin, United States, 53215
All Saints Cancer Center
Racine, Wisconsin, United States, 53405
Hospital Pirovano
Buenos Aires, Argentina, 1430
Hospital Britanico
Buenos Aires, Argentina, C1284AEB
Hospital Toru
Buenos Aires, Argentina, C1427ARN
Buenos Aires, Argentina, C1431FWO
Centro Oncologico de Cordoba
Cordoba, Argentina, X5000AAI
Mendoza, Argentina, 5500
Instituto Medico Privado
Resistencia, Argentina, 3900
Clinica Oncologica de Rosario
Rosario, Argentina, S2000dsk
ISIS Clinica Especializada
Sante Fe, Argentina, S3000FFU
Holy Spirit Hospital Northside
Chermside, QLD, Australia, 4032
Sunshine Coast Cancer Centre
Nambour, QLD, Australia, 4560
Sir Charles Gairdner Hospital
Nedlands, WA, Australia, 6009
Burnside War Memorial Hospital
Toorak Gardens, SA, Australia, 5065
Cliniques Univ St Luc
Brussels, Belgium, 1200
CHR Citadelle Liege
Liege, Belgium, 4000
Instituto Nacional do Cancer
Rio de Janeiro, Brazil, 20-231-050
Instituto de cancer Arnaldo
Sao Paulo, Brazil, 01221-020
Hospital Das Clinicas
Sao Paulo, Brazil, 05403-01
Regional Oncodispensary
Plovdiv, Bulgaria, 4004
Regional Oncodispensary
Rousse, Bulgaria, 7000
Regional Oncodispensary
Shoumen, Bulgaria, 9700
Regional Oncodispensary
Sofia, Bulgaria, 1233
UMHAT "Queen Joanna"
Sofia, Bulgaria, 1527
National Specialized Hospital
Sofia, Bulgaria, 1756
Regional Oncodispensary
Stara Zagora, Bulgaria, 6003
MHAT "St Marina"
Varna, Bulgaria, 9010
Regional Oncodispensary
Veliko Tarnovo, Bulgaria, 5000
Hong Kong
Princess Margaret Hospital
Hong Kong, Hong Kong
Queen Elizabeth Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Tuen Mun Hospital
Hong Kong, Hong Kong
Hadassah Medical Center
Jerusalem, Israel, 91120
Sourasky Medical Center
Tel-Aviv, Israel, 64239
Sheba Medical Center
Tel-Hashomer, Israel, 52621
Azienda Ospedaliera Univ
Genova, Italy, 16132
Ist Nazion per Ricerca Cancro
Genova, Italy, 16132
Univ degli Studi di Napoli
Napoli, Italy, 80131
Azienda Ospedaliera
Parma, Italy, 43100
Azienda Osper di Perugia
Perugia, Italy, 06159
Divisione Onc Med dell'Azienda
Udine, Italy, 33100
Torre Medica Cristobal Colon
Acapulco, Mexico, 39670
Inst Nacional de Cancerologia
Distrito Federal, Mexico, 14080
Merida, Mexico, 97500
Hospital de Especialidades
Torreon, Coahuila, Mexico, 27200
Philippine General Hospital
Manila, Luzon, Philippines, 1000
The Medical City
Pasig City, Luzon, Philippines, 1605
Veterans Memorial Medical Ctr
Quezon City, Luzon, Philippines, 1114
Perpetual Succour Hospital
Cebu City, Visayas, Philippines, 6000
Univ of Santo Tomas Hospital
Manila, Philippines, 1008
St Luke's Medical Center
Quezon City, Philippines, 1102
Centrul de Onc Medical Lasi
Iasi, Romania, 700106
Spitalul Clinic Judetean Sibiu
Sibiu, Romania, 550245
Spitalul Judetean de Urgente
Suceava, Romania, 720237
National Cancer Center
Singapore, Singapore, 169610
Corporacio Sanitaria Parc
Sabadell, Barcelona, Spain, 08208
Hospital de Cruces
Barakaldo, Spain, 48903
Hospital del Mar
Barcelona, Spain, 08003
Hospital Clinic i Provincial
Barcelona, Spain, 08036
Hospital Universitario
La Laguna, Spain, 38320
Instituto Valenciano Oncologia
Valencia, Spain, 46009
Hospital Clinico Universitario
Valencia, Spain, 46010
China Medical Univ Hosp
Taichung, Taiwan, 404
National Taiwan University
Taipei, Taiwan, 112
Taichung Veterans Gen Hosp
Taiwan, Taiwan, 407
Bumrungrad International Hosp
Bangkok, Thailand, 10110
National Cancer Institute
Bangkok, Thailand, 10400
Pramongkutklao Hospital
Bangkok, Thailand, 10400
Siriraj Hospital
Bangkok, Thailand, 10700
Maharaj Nakorn Chiang Mai Hosp
Chiangmai, Thailand, 50200
United Kingdom
Bristol Heamatology & Onc Ctr
Bristol, United Kingdom, BS2 8ED
Sponsors and Collaborators
Genentech, Inc.
Study Director: Donald Strickland, M.D. Genentech, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Genentech, Inc. Identifier: NCT00257608     History of Changes
Other Study ID Numbers: AVF3671g
BO20800 ( Other Identifier: Hoffmann-La Roche )
First Posted: November 23, 2005    Key Record Dates
Results First Posted: March 15, 2016
Last Update Posted: April 18, 2016
Last Verified: March 2016

Keywords provided by Genentech, Inc.:
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action